Increasing number of government initiatives to tackle increasing influenza outbreaks around the world will fuel the market growth of rapid influenza diagnostic tests over the coming years. As older people are known to be more vulnerable to the influenza virus, an increase in the geriatric population would also play a key role in growing the growth of the industry. Recent technological advances in the manufacturing of advanced diagnostic tests for influenza will serve as a major driving force for market growth across the globe. Furthermore, rising incidence of chronic diseases such as CVDs and diabetes worldwide is anticipated to increase the risk of influenza among the global patient pool. The prevalence of diabetes is expected to surpass 400 million by 2030, as per the International Diabetes Federation (IDF). Therefore, the above-mentioned variables would boost market growth over the projected period.

Adroit Market Research report on global rapid influenza diagnostics market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities, and challenges. The market has been studied for the period 2018 to 2028, with the base year of estimation as 2019 and forecast from 2020 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the market competition with Porter's five forces analysis and company positioning based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global rapid influenza diagnostics market have been studied in detail.

North America currently holds the largest share in Rapid Influenza Diagnostics market owing to the presence of significant number of major players across the region along with growing investments by the established firms. Regional development is due to rising influenza prevalence worldwide. Because of the large patient population, the U.S. dominates the North American rapid influenza diagnosis market. As per the Center for Disease Control and Prevention (CDC), over the past 3 years, approximately 30,000 Americans were hospitalized for influenza. Increasing government measures to avoid influenza outbreaks in the area would further push the rapid market growth of influenza diagnostic tests.

However, Asia Pacific is going to record growth at a faster pace on account of growing geriatric population especially across emerging economies such as India, China, and Japan in particular. Furthermore, the market growth across the Asia Pacific region is attributed to rising government focus on development of advanced healthcare facilities for the growing population.

The prominent players operating in global rapid influenza diagnostics market includes DiaSorin Molecular LLC, BD, SA Scientific, Coris BioConcept, Meridian Bioscience Inc., Abbott, Analytik Jena, F. Hoffmann-La Roche Ltd, Quidel Corporation, and Princeton BioMeditech Corporation among other prominent players.

Key segments of the global rapid influenza diagnostics market

Product Overview, 2018-2028 (USD Million)

• RIDT for Influenza A
• RIDT for Influenza B

End-Use Overview, 2018-2028 (USD Million)

• Hospitals
• Diagnostics Centers
• Research Laboratories

Regional Overview, 2018-2028 (USD Million)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • United Kingdom
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• South America
  • Brazil
  • Mexico
  • Rest of South America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East and Africa